Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1
Vectored gene delivery of HIV-1 broadly neutralizing antibodies (bNAbs) using recombinant
adeno-associated virus (rAAV) is a promising alternative to conventional vaccines for …
adeno-associated virus (rAAV) is a promising alternative to conventional vaccines for …
Pre-clinical data supporting immunotherapy for HIV using CMV-HIV-specific CAR T cells with CMV vaccine
T cells engineered to express HIV-specific chimeric antigen receptors (CARs) represent a
promising strategy to clear HIV-infected cells, but to date have not achieved clinical benefits …
promising strategy to clear HIV-infected cells, but to date have not achieved clinical benefits …
Antibody responses to the HIV-1 envelope high mannose patch
CN Daniels, KO Saunders - Advances in immunology, 2019 - Elsevier
Neutralizing antibodies against human immunodeficiency virus subtype 1 (HIV-1) bind to its
envelope glycoprotein (Env). Half of the molecular mass of Env is carbohydrate making it …
envelope glycoprotein (Env). Half of the molecular mass of Env is carbohydrate making it …
Blocking α4β7 integrin delays viral rebound in SHIVSF162P3-infected macaques treated with anti-HIV broadly neutralizing antibodies
I Frank, M Cigoli, MS Arif, MD Fahlberg… - Science translational …, 2021 - science.org
Anti-HIV broadly neutralizing antibodies (bNAbs) may favor development of antiviral
immunity by engaging the immune system during immunotherapy. Targeting integrin α4β7 …
immunity by engaging the immune system during immunotherapy. Targeting integrin α4β7 …
[HTML][HTML] Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir
Broadly neutralizing antibodies (bNAbs) against HIV-1 are under evaluation for both
prevention and therapy. HIV-1 sequence diversity observed in most HIV-infected individuals …
prevention and therapy. HIV-1 sequence diversity observed in most HIV-infected individuals …
On the road to a HIV cure: moving beyond Berlin and London
AIDS was first described as a new immunodeficiency syndrome in 1981. 1 The relatively
short history of human immunodeficiency virus (HIV) medicine is marked by major …
short history of human immunodeficiency virus (HIV) medicine is marked by major …
HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6
T Moshoette, MA Papathanasopoulos, MA Killick - Virology Journal, 2022 - Springer
The recently published AMP trial (HVTN 703/HPTN 081 and HVTN704/HPTN 085) results
have validated broad neutralising antibodies (bNAbs) as potential anti-HIV-1 agents …
have validated broad neutralising antibodies (bNAbs) as potential anti-HIV-1 agents …
Employing broadly neutralizing antibodies as a human immunodeficiency virus prophylactic & therapeutic application
C Ding, D Patel, Y Ma, JFS Mann, J Wu… - Frontiers in …, 2021 - frontiersin.org
Despite the discovery that the human immunodeficiency virus 1 (HIV-1) is the pathogen of
acquired immunodeficiency syndrome (AIDS) in 1983, there is still no effective anti-HIV-1 …
acquired immunodeficiency syndrome (AIDS) in 1983, there is still no effective anti-HIV-1 …
Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies
P Zhou, H Wang, M Fang, Y Li, H Wang, S Shi… - PLoS …, 2019 - journals.plos.org
Recently identified broadly neutralizing antibodies (bnAbs) show great potential for clinical
interventions against HIV-1 infection. However, resistant strains may impose substantial …
interventions against HIV-1 infection. However, resistant strains may impose substantial …
[HTML][HTML] Adeno-associated virus-vectored delivery of HIV biologics: The promise of a “single-shot” functional cure for HIV infection
PA Hahn, MA Martins - Journal of Virus Eradication, 2023 - Elsevier
The ability of immunoglobulin-based HIV biologics (Ig-HIV), including broadly neutralizing
antibodies, to suppress viral replication in pre-clinical and clinical studies illustrates how …
antibodies, to suppress viral replication in pre-clinical and clinical studies illustrates how …